North China Pharmaceutical HUAKUN Hebei BIOTECHNOLOGY Co., Ltd.

Main study objectives To study the pharmacokinetic behavior of the test preparation fospropin tenofovir tablets 25 mg and the reference preparation fospropin tenofovir tablets (Vemlidy®) 25 mg in Chinese healthy subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations under fasting and fed conditions. Secondary study objectives To evaluate the safety of the test preparation fospropin tenofovir tablets 25 mg and the reference preparation fospropin tenofovir tablets (Vemlidy®) 25 mg in healthy people.

Main study objectives: To investigate the pharmacodynamic characteristics of a single injection of the test preparation nadroparin calcium injection and the reference preparation nadroparin calcium injection in healthy adult Chinese subjects and to evaluate the bioequivalence of the two preparations. Secondary study objectives: To evaluate the safety of a single administration of the test preparation and the reference preparation in healthy adult Chinese subjects.

Main objective: To compare the differences in absorption extent and absorption rate between the test preparation and the reference preparation of emtricitabine and tenofovir alafenamide tablets (II) (emtricitabine 200 mg and tenofovir alafenamide 25 mg) (trade name: DESCOVY®) produced by Patheon Inc. (license holder: Gilead Sciences Ireland UC) in healthy Chinese adult subjects, and to investigate the bioequivalence of the two preparations. Secondary objective: To observe the safety and tolerability of the test preparation emtricitabine and tenofovir alafenamide tablets (II) and the reference preparation emtricitabine and tenofovir alafenamide tablets (II) (DESCOVY®) in healthy Chinese adult subjects according to the provisions of relevant bioequivalence studies.